Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by KATSUHIRO, I.
Right arrow Articles by OGAWA, M.
Right arrow Search for Related Content
PubMed
Right arrow Articles by KATSUHIRO, I.
Right arrow Articles by OGAWA, M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Japanese Journal of Clinical Oncology 9:239-246 (1979)
© 1979 Foundation for Promotion of Cancer Research

research-article

Antitumor Activity of Ifosfamide against Nude Mice Xenograft and Results of Clinical Investigation

INOUE KATSUHIRO, M.D., HIROSHI UEOKA, M.D., SHUICHI FUJIMOTO, M.S., JIRO INAGAKI, M.D., NOBORU HORIKOSHI, M.D., YASUO TAKANO, M.D., EIICHI NAGURA, M.D., SHIRO MUROSAKI, M.D., TADASHI KOBAYASHI, M.D. and MAKOTO OGAWA, M.D.

Department of Clinical Oncology, Cancer Institute Hospital and Division of Clinical Chemotherapy, Cancer Chemotherapy Center Tokyo

Reprint requests: Katsuhiro Inoue, M.D., Department of Clinical Oncology, Cancer Institute Hospital and Division of Clinical Chemotherapy, Cancer Chemotherapy Center, 1-37-1 Kami-Ikebukuro, Toshima-ku, Tokyo 170, Japan.

Received July 18, 1979; An evaluation of the effectiveness of ifosfamide against a xenograft of a mammary breast carcinoma and clinical evaluation in patients with advanced malignant tumors refractory to previous chemo- and radiotherapy was performed. Ifosfamide showed high antitumor activity against the xenograft of mammary breast carcinoma MX-1, but the antitumor activity of cyclophosphamide was higher.

Combination chemotherapy with ifosfamide was investigated in 26 patients. Except in one case, ifosfamide was given in combination with other anticancer agents as follows: regimen 1 (vincristine at 1 mg/body weekly, ifosfamide at 1.2g/m2/d and prednisolone at 40 mg/m2/d on days 1 to 5); regimen II (vincristine at 1 to 1.5 mg/body weekly, ifosfamide at 2.0 g/m2/d and prednisolone at 40 mg/m2/d on days 1 to 5); and regimen III (Bischlorethyl nitrosourea, BCNU at 100mg/m2 at six-week intervals, ifosfamide at 2.0 g/m2/d and prednisolone at 60 mg/m2/d on days 1 to 5). For four patients, ifosfamide at 1.2 g/m2/d on days 1 to 5 was given with vinblastine, actinomycin-D, Cis-dichloro-diammine platinum (cis-DDP) or bleomycin. In patients with advanced malignant tumors refractory to previous chemo-and radiotherapy, the response to all regimens was minimal. In regimen II and III, there was increased hematological, genitourinary and central nervous system toxicity due to dose escalation of ifosfamide, as compared with regimen I. Therefore, dose escalation of more than 1.2g/m2/d is not recommended.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.